FDA Approves Celltrion’s Avtozma for Pediatric COVID-19 in High-Risk Patients
Celltrion announced on October 7 that the U.S. Food and Drug Administration has approved an expanded pediatric indication for the intravenous...
Search results for "biosimilar"
Zymfentra U.S. Sales Surge 176% as Celltrion’s Remsima Franchise Eyes 1 Trillion Won Annual Revenue
Biopharmaceutical company Celltrion announced on Aug. 27 that combined first-half sales of its subcutaneous infliximab products—Remsima SC and...
Celltrion Secures Historic FDA Interchangeability Status for Truxima
Celltrion announced on the 1st that the U.S. Food and Drug Administration has granted interchangeable status to Truxima...
Celltrion to Acquire French Healthcare Specialist Gifrer, Eyeing European Pharmacy Market
Celltrion announced on the 12th its acquisition of Gifrer, a French healthcare specialist with a 114-year history.
A Milestone for K-Bio: Celltrion’s Truxima Surpasses Global Blockbuster Rituxan in U.S. Prescriptions
Truxima , a blood cancer treatment developed by Celltrion, has become the first Korean-made biosimilar to rank number...
Celltrion to Double Production Capacity with 1.2 Trillion Won Investment
Celltrion has announced a massive expansion across three of its major facilities in South Korea and the United States,...
Celltrion Secures Canadian Approval for ‘Steqeyma’ Autoinjector Formulation
Celltrion announced on March 20, 2026, that it has received additional approval from Health Canada for the autoinjector...
Launch of 'TrumpRX' Sells Drugs at Steep Discounts: Will Celltrion and Samsung Biologics Face Price Pressure?
The prescription drug sales platform 'TrumpRX', named after U. S. President Donald Trump, has officially launched.
Samsung Bioepis Achieves Record Sales of 1.672 Trillion Won Last Year
Samsung Bioepis achieved its highest performance last year in terms of sales. Excluding short-term milestone revenues,...
Samsung Bioepis to Directly Sell Ophthalmic Drug Baivubiz in Europe
Samsung Bioepis announced on the 4th that it has recovered the European commercialization rights for the ophthalmic...